Nöroimmünolojide İlaç Rehberi

Haghikia, Aiden, Georg Schett, and Dimitrios Mougiakakos. "B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases." The Lancet Neurology 23.6

Gold R, Buttgereit F, Toyka KV. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol. 2001;117:1–8.

Rizvi, Syed, Jonathan F. Cahill, and Patricia K. Coyle, eds. Clinical Neuroimmunology. Springer International Publishing, 2020.

Waljee AK, Rogers MAM, Lin P, Singal AG, Stein JD, Marks RM, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017 Apr 12;357:j1415.

Stanbury RM, Graham EM. Systemic corticosteroid therapy-- side effects and their management. Br J Ophthalmol. 1998 Jun 1;82(6):704-8.

Buttgereit F, da Silva JAP, Boers M, Burmester G-R, Cutolo M, Jacobs J, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002 Aug 1;61(8):718-22.

Yasir M, Goyal A, Bansal P, Sonthalia S. Corticosteroid adverse effects. In: StatPearls . Treasure Island (FL):StatPearls Publishing; 2021.

La Mantia L, Eoli M, Milanese C, Salmaggi A, Dufour A, Torri V. Doubleblind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses. Eur Neurol. 1994;34(4):199-203

Bracken, M.B. Shepard, M.J. Collins, W.F. Holford, T.R. Young, W. Baskin, D.S. Eisenberg, H.M. Flamm, E. Leo-Summers, L. & J. Maroon: A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 322, 1405- 1411 (1990)

Sebire, G. Hollenberg, H. Meyer, L. Huault, G. Landrieu, P. & M. Tardieu: High dose methylprednisolone in severe acute transverse myelopathy. Arch Dis Child 76, 167-168 (1997)

Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med. 1992;326:581–8.

Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev. 2000;1998(2)

Watanabe, S.; Misu, T.; Miyazawa, I.; Nakashima, I.; Shiga, Y.; Fujihara, K.; Itoyama, Y. Low-dose corticosteroids reduce relapses in neuromyelitis optica: A retrospective analysis. Mult. Scler. 2007, 13, 968–974

Ramanathan, Sudarshini, et al. "Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination." Journal of Neurology, Neurosurgery & Psychiatry 89.2 (2018): 127-137. (2024): 615-624.

Stingl, Cory, Kathleen Cardinale, and Heather Van Mater. "An update on the treatment of pediatric autoimmune encephalitis." Current Treatment Options in Rheumatology 4 (2018): 14-28.

Doets, Alex Y., et al. "Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain‐Barré syndrome." Cochrane Database of Systematic Reviews 1 (2020).

Akman-Demir, Gülflen. "Behçet Hastalığı’nda Nörolojik Tutulum."

Ugarte A , Danza A , Ruiz-Irastorza G. Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. Curr Opin Rheumatol 2018;30:482–9

Buttgereit F , da Silva JA , Boers M et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002;61:718–22.

Motta, Francesca, et al. "Steroid-induced osteonecrosis." Journal of translational autoimmunity 5 (2022): 100168.

Alves C, Robazzi TCV, Mendonça M. Withdrawal from glucocorticosteroid therapy: clinical practice recommendations. J Pediatr (Rio J). 2008 May-Jun;84(3):192-202.

Sevim S. Relapses in multiple sclerosis: definition, pathophysiology, features, imitators, and treatment. Turk J Neurol. 2016;22(3):99-108.

Arnason B, Berkovich R, Catania A, Lisak RP, Zaidi M. Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. Multiple Sclerosis. 2013;19(2):130-6.

Lisak RP, Benjamins JA. Melanocortins, melanocortin receptors and multiple sclerosis. Brain Sci. 2017;7(8):104.

DEMİR, Büşra Şeniz, Zehra Büşra AZiZOĞLU, and Ahmet EKEN. "Nöroimmünolojik ve Nörodejeneratif Hastalıklarda İmmün Sistem ve İnflamatuar Mekanizmalar." Turkiye Klinikleri Pediatric Neurology-Special Topics 4.2 (2023): 1-20.

Paprocka, Justyna, et al. "Effectiveness of ACTH in patients with infantile spasms." Brain Sciences 12.2 (2022): 254.

Mesut, Güngör, et al. "The Effectiveness of Acth Therapy According to Etiology in Patients with West Syndrome and Its Long-Term Effects on Bone Mineral Metabolism and Adrenal Pathway." Çocuk Dergisi 22.1 (2022): 30-37.

Baram TZ, Mitchell WG, Tournay A, et al. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics 1996; 97:375.

Hodgeman RM, Kapur K, Paris A, et al. Effectiveness of once-daily high-dose ACTH for infantile spasms. Epilepsy Behav 2016; 59:4.

Hrachovy RA, Frost JD Jr, Glaze DG. High-dose, long-duration versus low-dose, short-duration corticotropin therapy for infantile spasms. J Pediatr 1994; 124:803.

Yanagaki S, Oguni H, Hayashi K, et al. A comparative study of high-dose and low-dose ACTH therapy for West syndrome. Brain Dev 1999; 21:461.

Feutren G, Abeywickrama K, Friend D, von Graffenried B: Renal function and blood pressure in psoriasis patients treated with cyclosporine. Br J Dermatol 1990;122(Suppl 36):57-69.

GÜLEÇ, Bade, and Sabahattin SAİP. "Multipl Skleroz; Atak ve Tedavisi." Turkiye Klinikleri Neurology-Special Topics 13.4 (2020): 68-73.

Broen JCA, van Laar JM. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):167-78

Ryan m, North K, muntoni F. myasthenia and disorders of the neuromuscular junction. ın: Arzimanoglou A, o’Hare A, johnston m, ouvrier R, eds. Aicardi’s diseases of the Nervous System in Childhood. 4th ed. london: mac Keith press; 2018. p.1294-309.

Martínez Torre S, Gómez Molinero I, Martínez Girón R. An Update On Myasthenia Gravis. Semergen. 2018;44(5):351-4. Doi: 10.1016/J.Semerg.2018.01.003

Deymeer F. History of myasthenia gravis revisited. Noro psikiyatr Ars. 2020;58(2):154-62. doi: 10.29399/npa.27315.

Andrews pı. Autoimmune myasthenia gravis in childhood. Semin Neurol. 2004;24(1):101-10. doi: 10.1055/s-2004-829591.

McWilliam M, Khan U. Azathioprine and the neurologist. Pract Neurol. 2020 Feb;20(1):69-74.

ALTUN, Yaşar. "Mitoxantron Azathioprine ve Diğer İmmünsupressan İlaçlar." Turkiye Klinikleri Neurology-Special Topics 13.4 (2020): 148-151.

Chan ESL, Cronstein BN. Mechanisms of action of methotrexate. Bull Hosp Joint Dis (2013). 2013;71 Suppl 1:S5-8.

Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020 Mar;16(3):145-54.

Ashtari, F.; Savoj, M.R. Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: A randomized controlled trial. J. Res. Med. Sci. 2011, 16, 457–462

Stark, J.W.; Josephs, L.; Dulak, D.; Clague, M.; Sadiq, S.A. Safety of long-term intrathecal methotrexate in progersive forms of MS. Ther. Adv. Neurol. Disord. 2019, 12, 1–8.

Hartmann, J.; Rivner, M.H. Methotrexate in myasthenia gravis. Clin. Neurophysiol. 2009, 120, e123–e124.

46.Gold, R.; Schneider-Gold, C. Current and future standards in treatment of myasthenia gravis. Neurotherapeutics 2008, 5, 535–541.

Abdou, A.M. Methotrexate for treatment of myasthenia gravis. Neurology 2007, 62 (Suppl. S1), 300–301.

Kalb RE, Strober B, Weinstein G, Lebwahl H. Methotrexate and psoriasis. 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009;60:824-37.

Nast A, Boehncke WH, Mrowietz U et al. Guidelines on the teratment of psoriasis vulgaris (English version) update. J Dtsch Dermatol Ges 2012;10:51-99.

Okuda DT. Immunosuppressive treatments in multiple sclerosis. Handb Clin Neurol. 2014;122:503-11

Romão VC, Lima A, Bernardes M, Canhão H, Fonseca JE. Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity? Immunol Res. 2014 Dec;60(2-3):289-310.

Bedoui Y, Guillot X, Sélambarom J, Guiraud P, Giry C, Jaffar-Bandjee MC, et al. Methotrexate an old drug with new tricks. Int J Mol Sci. 2019 Oct 10;20(20):5023.

Michel L, Vukusic S, De Seze J, Ducray F, Ongagna JC, Lefrère F, et al. Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients. J Neurol Neurosurg Psychiatry. 2014;85:279-83

Rahman ANA, Tett SE, Staatz CE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease. Clin Pharmacokinet. 2013 May;52(5):303-31.

Lee A, Bridges LR, Lloyd M, Barker R, Wren DR, Galtrey CM. Epstein- Barr virus associated CNS lymphoproliferative disorder after longterm immunosuppression. Pract Neurol. 2020 Feb;20(1):83-6.

Roche laboratories. Our products: Cellcept: Complete product information. Roche U.S: Pharmaceuticals 2000.

Kappos L, Patzold U, Dommasch D, Poser S, Haas J, Krauseneck P, et al. Cyclosporine versus azathioprine in the long term treatment of multiple sclerosis; results of German multicenter study. Ann Neurol. 1988;23(1):56-63

Rudge P, Koetsier JC, Mertin J, Mispelblom Beyer JO, Van Walbeek HK, Clifford Jones R, et al. Randomised double-blind controlled trial of cyclosporine in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1989;52(5):559-65

Maza A, Montaudie H, Sbidian E, et al: Oral cyclosporin in psoriasis: a systemic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J EurAcad Dermatol Venereol 2011;25(Suppl 2):19-27.

Kovarsky J. Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases. Semin Arthritis Rheum. 1983;12:359–72.

Ahlmann M, Hempel G. The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. Cancer Chemother Pharmacol. 2016 Oct;78(4):661-71.

Taşkırdı, Elif Didinmez, and Nihal Olgaç Dündar. "İmmünomodulatuar Tedavi ve Nöroimmünolojide Yeni Tedavi Seçenekleri." Turkiye Klinikleri Pediatric Neurology-Special Topics 4.2 (2023): 279-288.

Okuda DT. Immunosuppressive treatments in multiple sclerosis. Handb Clin Neurol. 2014;122:503-11

Makhani N, Gorman MP, Branson HM, Stazzone L, Banwell BL, Chitnis T. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology. 2009;72:2076–82.

Stillwell TJ, Benson Jr RC. Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer. 1988;61:451–7.

De Ridder D, van Poppel H, Demonty L, et al. Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. J Urol. 1998;159:1881–4.

Khizroeva J, Nalli C, Bitsadze V, Lojacono A, Zatti S, Andreoli L, et al. Infertility in women with systemic autoimmune diseases. Best Pract Res Clin Endocrinol Metab. 2019 Dec;33(6):101369.

Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009 Nov;6(11):638-47.

Van den Brand JAJG, van Dijk PR, Hofstra JM, Wetzels JFM. Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1066-73.

Whittam DH, Tallantyre EC, Jolles S, Huda S, Moots RJ, Kim HJ, et al. Rituximab in neurological disease: principles, evidence and practice. Pract Neurol. 2019 Feb;19(1):5-20.

Ellwardt E, Rolfes L, Klein J, Pape K, Ruck T, Wiendl H, et al. Ocrelizumab initiation in patients with MS: a multicenter observational study. Neurol Neuroimmunol Neuroinflamm. 2020 Apr 9;7(4):e719.

Liossis SN, Sfikakis PP. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol. 2008;127:280–5.

Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin’s lymphoma. Drugs. 2007;67:333–50.

Schuna AA. Rituximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2007;27:1702–10.

Cree BA et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64:1270–2.

Salzer J, Lycke J, Wickström R, Naver H, Piehl F, Svenningsson A. Rituximab in paediatric onset multiple sclerosis: a case series. J Neurol. 2016;263(2):322-6.

Dale RC, Brilot F, Duffy LV, Twilt M, Waldman AT, Narula S, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83(2):142-50.

Ghezzi A, Banwell B, Bar-Or A, Chitnis T, Dale RC, Gorman M, et al. Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations. Mult Scler. 2021;27(12):1814-22.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24;380(9856):1829-39

Coles A, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol. 1999;46(3):296–304.

Straus Farber R, Harel A, Lublin F. Novel agents for relapsing forms of multiple sclerosis. Annu Rev Med. 2016;67:309-21.

Flynn JM, Byrd JC. Campath-1H monoclonal antibody therapy. Curr Opin Oncol. 2000;12:574-81.

Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006;253:98–108.

Coles A, Deans J, Compston A. Campath-1H treatment of multiple sclerosis: lessonsfrom the bedside for the bench. Clin Neurol Neurosurg. 2004;106:270–4.

Fox E et al. Two-years results with alemtuzumab in patients with active relapsingremitting multiple sclerosis who have failed licensed beta interferon therapies. Mult Scler. 2007;13:A558.

Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786–801.

UZUNER, Gülnur TEKGÖL, and Nevzat UZUNER. "Alemtuzumab." Turkiye Klinikleri Neurology-Special Topics 13.4 (2020): 144-147.

Berger T, Elovaara I, Fredrikson S, McGuigan C, Moiola L, Myhr K-M, et al. Alemtuzumab use in clinical practice: recommendations from European Multiple Sclerosis Experts. CNS Drugs. 2017 Jan;31(1):33- 50.

Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, et al. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CAREMS II studies and the CAMMS03409 extension study. Mult Scler. 2019 Oct;25(12):1605-17.

Shirani A, Stüve O. Natalizumab for Multiple Sclerosis: a case in point for the impact of translational neuroimmunology. J Immunol. 2017 Feb 15;198(4):1381-6.

Goodin DS, Cohen BA, O’Connor P, Kappos L, Stevens JC. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;71:766–73.

Putzki N, Kollia K, Woods S, Igwe E, Diener HC, Limmroth V. Natalizumab is effective as second line therapy in the treatment of relapsing remitting MS. Eur J Neurol. 2009;16:424–6.

Miller DH, Khan oA, Sheremata WA, Blumhardt lD, Rice Gp, libonati MA, et al. ınternational Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348(1):15-

GÖKÇE, Şeyda Figül. "Natalizumab." Turkiye Klinikleri Neurology-Special Topics 13.4 (2020): 141-143.

Ryerson LZ, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016 Jul 14;87(8):885-9.

Schwab N, Schneider-Hohendorf T, Melzer N, Cutter G, Wiendl H. Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification. Neurology. 2017 Mar 21;88(12):1197-1205

Polman CH, o'Connor pW, Havrdova E, Hutchinson M, Kappos l, Miller DH, et al. AFFıRM ınvestigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.

Hermann R, Karlsson MO, Novakovic AM, Terranova N, Fluck M, Munafo A. The clinical pharmacology of cladribine tablets for the treatment of relapsing multiple sclerosis. Clin Pharmacokinet. 2019 Mar 5;58(3):283-97.

Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Sørensenet PS, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):416-26.

Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, et al. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler. 2011 May 1;17(5):578-93.

TURGUT, Nilda. "Kladribin." Turkiye Klinikleri Neurology-Special Topics 13.4 (2020): 128-131.

Signori A, Saccà F, Lanzillo R, Maniscalco GT, Signoriello E, Repice AM, et al. Cladribine vs other drugs in MS: merging randomized trial with real-life data. Neurol Neuroimmunol Neuroinflamm. 2020;7(6):e878.

Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24(12):1594-604.

Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010 Nov;9(11):883-97

Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics. 2017;14(4):859-73.

Chun J, Kihara Y, Jonnalagadda D, Blaho VA. Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders. Annu. Rev. Pharmacol.Toxicol. 2019;59:149–70.

KURTULUŞ, Fatma. "Fingolimod." Turkiye Klinikleri Neurology-Special Topics 13.4 (2020): 122-127.

Fragoso YD, Adoni T, Gomes S, Gonçalves MVM, Parolin LF, Rosa G, et al. Severe Exacerbation of Multiple Sclerosis following withdrawal of fingolimod. Clin Drug Investig. 2019 Sep 1;39(9):909-13.

Calabresi, Peter A., et al. "Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial." The Lancet Neurology 13.6 (2014): 545-556.

Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401. .

Cohen JA, Chun J. Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis. Ann. Neurol. 2011;69:759–77.

Druart C, Sankari SE ,Pesch VV. Longterm safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis. Patient Related Outcome Measures. 2018:9 1–10.

Yoshii F, Moriya Y, Ohnuki T, Ryo M, Takahashi W. Neurological safety of fingolimod: an updated review. Clin Exp Neuroimmunol. 2017;8(3):233–43.

Diebold M, Sievers C, Bantug G, Sanderson N, Kappos L, Kuhle J, et al. Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis. J Autoimmun. 2018 Jan;86:39-50.

Gross CC, Schulte-Mecklenbeck A, Klinsing S, Posevitz-Fejfar A, Wiendl H, Klotz L. Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2016;3(1): e183.

Linker RA, Lee DH, Ryan S, Van Dam AM, Conrad R, Bista P, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134(3):678–92.

Moharregeh-Khiabani D, Linker RA, Gold R, Stangel M. Fumaric acid and its esters: an emerging treatment for multipl sclerosis. Current Neuropharmacology. 2009;7(1):60-4

Montes Diaz G, Hupperts R, Fraussen J, Somers V. Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies. Autoimmun Rev. 2018 ;17(12):1240-50.

Kürtüncü M. Multipl Skleroz : Oral Tedaviler. Karabudak R, editör.Temel ve Klinik Nöroimmunoloji. 1.Baskı. Ankara: Ada yayıncılık: 2013.p.395.

Scannevin RH, Chollate S, Jung MY, Shackett M, Patel H, Bista P, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway.J Pharmacol Exp Ther. 2012;341(1):274-84.

Fernández Ó, Giovannoni G, Fox RJ, Gold R, Phillips JT, Potts J, et al. Efficacy and Safety of Delayed-release Dimethyl Fumarate for relapsing-remitting Multiple Sclerosis in prior interferon users: an integrated analysis of DEFINE and CONFIRM. Clin Ther. 2017 Aug 1;39(8):P1671-9.

Blair HA. Dimethyl Fumarate: a review in relapsing-remitting MS. Drugs. 2019 Dec;79(18):1965-76.

Alroughani R, Das R, Penner N, Pultz J, Taylor C, Eraly S. Safety and efficacy of delayed-release dimethyl fumarate in pediatric patients with relapsing multiple sclerosis (FOCUS). Pediatr Neurol. 2018;83:19-24. doi: 10.1016/j.pediatrneurol. 2018.03.007.

Makhani N, Schreiner T. Oral dimethyl fumarate in children with multiple sclerosis: a dual-center study. Pediatr Neurol. 2016;57:101-4. doi: 10.1016/j.pediatrneurol. 2016.01.010.

Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014 Apr;74(6):659-74.

Ringshausen ı, Oelsner M, Bogner C, Peschel C, Decker T. The immunomodulatory drug leflunomide inhibits cell cycle progression of B-Cll cells. leukemia. 2008;22(3):635-8

li l, liu J, Delohery T, zhang D, Arendt C, Jones C. The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro. J Neuroimmunol. 2013;265(1-2):82-90.

Faissner S, Gold R. Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010. CNS Drugs. 2018;32(3):269- 87.

Taşkapılıoğlu Ö. Recent Advances in the Treatment for Multiple Sclerosis; Current New Drugs Specific for Multiple Sclerosis. Arch Neuropsychiatry 2018;55: (Supplement 1): S15−S20

Paik J. Teriflunomide: pediatric first approval. Paediatr Drugs. 2021;23(6):609- 13.

Macaron G, Feng J, Moodley M, Rensel M. Newer treatment approaches in pediatric-onset multiple sclerosis. Curr Treat Options Neurol. 2019;21(10):50.

Aly l, Hemmer B, Korn T. From leflunomide to Teriflunomide: Drug Development and ımmunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis. Curr Neuropharmacol. 2017;15(6):874-91.

Chan A, de Seze J, Comabella M. Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis. CNS Drugs. 2016;30(1):41

Klotz l, Havla J, Schwab N, Hohlfeld R, Barnett M, Reddel S, et al. Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Ther Adv Neurol Disord. 2019 Apr 1;12:1756286419836571

Kieseier BC. The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs. 2011 Jun 1;25(6):491-502.

Calabresi, P.A.; Wilterdink, J.L.; Rogg, J.M.; Mills, P.; Webb, A.; Whartenby, K.A. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 2002, 58, 314–317.

Durelli L, Barbero P, Clerico M; INCOMIN Trial Study Group. A randomized study of two interferon-beta treatments in relapsingremitting multiple sclerosis. Neurology. 2006;26(12): 2264.

Sorensen PS. Neutralizing antibodies against interferon-beta. Ther Adv Neurol Disord 2008;1(2):125-41.

Bermel RA, Rudick RA. Interferon-beta treatment for multiple sclerosis. Neurotherapeutics. 2007 Oct;4(4):633-46.

Landi D, Albanese M, Fabio Buttari, Monteleone F, Boffa L, Rossi S et al. Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study. PLoS ONE. 2017;12(7): e0165415.

Hakkarainen KM, Juuti R, Burkill S, Geissbühler Y, Sabidó M, Popescu C, et al. Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden. Ther Adv Neurol Disord. 2020 Oct 7;13:1756286420951072.

McKeage K. Glatiramer Acetate 40 mg/mL in relapsing-remitting multiple sclerosis: a review. CNS Drugs. 2015 May;29(5):425-32.

Ziemssen T, Ashtamker N, Rubinchick S, Knappertz V, Comi G. Longterm safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis. Expert Opin Drug Saf. 2017 Feb;16(2):247-55. .

Ford C, Goodman AD, Johnson K, Kachuck N, Lindsay JW, Lisak R, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler. 2010Mar 1;16(3):342-50.

Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R; GALA Study Group. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013;73(6):705-13.

Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med. 1987; 317(7):408-14.

Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology. 1995;45(7):1268-76.

Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging—measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol. 2001;49(3):290-7.

Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 374(9700):1503-11.

Khan O, Rieckmann P, Boyko A, Selmaj K, Ashtamker N, Davis MD, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013;73(6):705-13.

Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9:1299.

Konuskan B, Anlar B. Treatment in childhood central nervous system demyelinating disorders. Dev Med Child Neurol. 2019;61(11):1281-8.

Bramlage CP, Schröder K, Bramlage P, Ahrens K, Zapf A, Müller GA, et al. Predictors of complications in therapeutic plasma exchange. J Clin Apher. 2009;24(6):225-31.

Acosta CM, Cortes C, MacPhee H, Namaka MP. Exploring the role of nerve growth factor in multiple sclerosis: implications in myelin repair. CNS Neurol Disord Drug Targets. 2013;12(8):1242-56.

Cutter G. Indirect comparison of glatiramer acetate 40 mg/mL TIW and 20 mg/mL QD dosing regimen effects on relapse rate: results of a predictive statistical model. Poster, ECTRIMS, 2014 (Boston).

Bayry J, Thirion M, Misra N, Thorenoor N, Delignat S, Lacroix- Desmazes S, et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol Sci. 2003 Oct;24 Suppl 4:S217-21.

Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9:1299.

Berger M. Adverse effects of IgG therapy. J Allergy Clin Immunol Pract. 2013 Nov-Dec;1(6):558-66.

Salameh JS, Deeb W, Burawski L, Wright S, Souayah N. Safety and efficacy of subcutaneous immunoglobulin in the treatment of neuromuscular disorders. J Clin Neuromuscul Dis. 2016 Mar;17(3):110-9.

Lemaire A, Parquet N, Galicier L, Boutboul D, Bertinchamp R, Malphettes M, et al. Plasma exchange in the intensive care unit: technical aspects and complications. J Clin Apher. 2017 Dec;32(6):405-12.

Okafor C, Ward DM, Mokrzycki MH, Weinstein R, Clark P, Balogun RA. Introduction and overview of therapeutic apheresis. J Clin Apher. 2010;25(5): 240-9.

Williams ME, Balogun RA. Principles of separation: indications and therapeutic targets for plasma exchange. Clin J Am Soc Nephrol. 2014;9(1): 181-90.

Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidencebased guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011; 76(3):294-300.

Meca-Lallana JE, Hernández-Clares R, León-Hernández A, Genovés Aleixandre A, Cacho Pérez M, Martín-Fernández JJ. Plasma exchange for steroid-refractory relapses in multiple sclerosis: an observational, MRI pilot study. Clin Ther 2013;35(4):474-85.

Stork L, Ellenberger D, Beißbarth T, et al. Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis. JAMA Neurol. 2018;75(4):428–35.

Konuskan B, Anlar B. Treatment in childhood central nervous system demyelinating disorders. Dev Med Child Neurol. 2019;61(11):1281-8.

Pham HP, Staley EM, Schwartz J. Therapeutic plasma exchange- a brief review of indications, urgency, schedule, and technical aspects. Transfus Apher Sci. 2019 Jun 1;58(3):P237-46.

Osman C, Jennings R, El-Ghariani K, Pinto A. Plasma exchange in neurological disease. Pract Neurol. 2020 Apr;20(2):92-9.

GÜLEÇ, Bade, and Sabahattin SAİP. "Multipl Skleroz; Atak ve Tedavisi." Turkiye Klinikleri Neurology-Special Topics 13.4 (2020): 68-73.

SBIm. Calendário de vacinação pacientes especiais 2019-2020. Sociedade Brasileira de Imunizações; 2019.

Bühler S, Eperon G, Ribi C, Kyburz D, van Gompel F, Visser LG, et al. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly. 2015 Jul 28;145:w14159.

Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014 Feb 1;58(3):309-18.

Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis. 2018 May;77(5):644-49.

Rahier JF, Ben-Horin S, Chowers Y, Conlon C, de Munter P, D’Haens G, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009 Jun 1;3(2):47-91.

Pitsiou GG, Kioumis IP. Pneumococcal vaccination in adults: does it really work? Respir Med. 2011 Dec 1;105(12):P1776-83.

Horsburgh Jr CR, Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med. 2011 Apr 14;364(15):1441-8.

Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009 Sep;50(3):661-2.

Natário A, Matias P, Weigert A. An update on immunosuppression for the HIV-positive kidney transplant recipient. Port J Nephrol Hypertens. 2012;26(2):139-47.

Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2011 Apr;70(4):616-23.

Mohseni M, Boniface MP, Graham C. Mononucleosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.